CCR2 and metabolic dysfunction-associated steatohepatitis: In contrast, it has been shown that the inactivation of CCR2 inhibits NASH in the liver [48] and that the genetic deletion of MCP-1 and CCR2 attenuates obesity and improves insulin resistance and hepatic steatosis [16,17].